{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:27:00Z","timestamp":1790630820409,"version":"4.1.0"},"reference-count":146,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005851","name":"Shahid Beheshti University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.intimp.2022.109046","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T02:33:04Z","timestamp":1657593184000},"page":"109046","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies"],"prefix":"10.1016","volume":"110","author":[{"given":"Maryam","family":"Noori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadi","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhan","family":"Abbasi Varaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Aria","family":"Nejadghaderi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davood","family":"Bashash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2022.109046_b0005","unstructured":"T.A. Ghebreyesus, WHO Director-General's opening remarks at the media briefing on COVID-19. 2020. Geneva: World Health Organization, 2020."},{"issue":"9","key":"10.1016\/j.intimp.2022.109046_b0010","doi-asserted-by":"crossref","first-page":"644","DOI":"10.34172\/aim.2020.78","article-title":"Case Fatality Rate of COVID-19: Meta-Analysis Approach","volume":"23","author":"Almasi-Hashiani","year":"2020","journal-title":"Arch. Iran Med."},{"issue":"10","key":"10.1016\/j.intimp.2022.109046_b0015","doi-asserted-by":"crossref","DOI":"10.1038\/d41573-021-00156-x","article-title":"Pfizer's COVID-19 vaccine secures first full FDA approval","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.intimp.2022.109046_b0020","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.intimp.2022.109046_b0025","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10269","key":"10.1016\/j.intimp.2022.109046_b0030","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.intimp.2022.109046_b0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect. Dis."},{"issue":"4","key":"10.1016\/j.intimp.2022.109046_b0040","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3390\/diagnostics11040579","article-title":"Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines","volume":"11","author":"Doroftei","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"10.1016\/j.intimp.2022.109046_b0045","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-021-00198-2","article-title":"A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990\u20132017","volume":"10","author":"Keykhaei","year":"2021","journal-title":"Experimental Hematol. & Oncology."},{"issue":"11","key":"10.1016\/j.intimp.2022.109046_b0050","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","article-title":"Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network","volume":"105","author":"Smith","year":"2011","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2022.109046_b0055","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01177-0","article-title":"COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)","volume":"14","author":"Pagano","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"11","key":"10.1016\/j.intimp.2022.109046_b0060","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1038\/s41409-020-0931-4","article-title":"COVID-19 outcomes in patients with hematologic disease","volume":"55","author":"Malard","year":"2020","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"10.1016\/j.intimp.2022.109046_b0065","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2020.04.006","article-title":"Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan","volume":"146","author":"Li","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2022.109046_b0070","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","article-title":"Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study","volume":"7","author":"Passamonti","year":"2020","journal-title":"Lancet Haematol."},{"issue":"5","key":"10.1016\/j.intimp.2022.109046_b0075","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41571-021-00487-z","article-title":"COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials","volume":"18","author":"Desai","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2022.109046_b0080","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.738915","article-title":"Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia","volume":"12","author":"Allegra","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2022.109046_b0085","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejca.2021.10.013","article-title":"Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis","volume":"159","author":"Tran","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.intimp.2022.109046_b0090","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj."},{"issue":"9","key":"10.1016\/j.intimp.2022.109046_b0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138237","article-title":"The Role of Google Scholar in Evidence Reviews and Its Applicability to Grey Literature Searching","volume":"10","author":"Haddaway","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2022.109046_b0100","unstructured":"G.A. Wells, B.S. D O'Connell, J. Peterson, V. Welch, M. Losos, P. Tugwell, The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Available from: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"issue":"1","key":"10.1016\/j.intimp.2022.109046_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2049-3258-72-39","article-title":"Metaprop: a Stata command to perform meta-analysis of binomial data","volume":"72","author":"Nyaga","year":"2014","journal-title":"Arch. Public Health"},{"issue":"7414","key":"10.1016\/j.intimp.2022.109046_b0110","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.intimp.2022.109046_b0115","doi-asserted-by":"crossref","unstructured":"H. Ali, D. Ngo, A. Aribi, S. Arslan, S. Dadwal, G. Marcucci, et al., Safety and tolerability of SARS-CoV2 emergency-use authorized vaccines for allogeneic hematopoietic stem cell transplant recipients, Transplantation and Cell. Therapy 2021;27(11):938. e1-. e6.","DOI":"10.1016\/j.jtct.2021.07.008"},{"key":"10.1016\/j.intimp.2022.109046_b0120","article-title":"Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy","volume":"1\u201310","author":"Cohen","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"10","key":"10.1016\/j.intimp.2022.109046_b0125","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29191","article-title":"Varicella-Zoster virus reactivation following SARS-CoV-2 immunization in two patients with leukemia","volume":"68","author":"Foster","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"issue":"10","key":"10.1016\/j.intimp.2022.109046_b0130","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3390\/vaccines9101209","article-title":"The COVID-19 mRNA BNT163b2 vaccine was well tolerated and highly immunogenic in young adults in long follow-up after haematopoietic stem cell transplantation","volume":"9","author":"Matkowska-Kocjan","year":"2021","journal-title":"Vaccines."},{"issue":"8","key":"10.1016\/j.intimp.2022.109046_b0135","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-021-04058-z","article-title":"Thromboembolism after COVID-19 vaccine in patients with preexisting thrombocytopenia","volume":"12","author":"Mauriello","year":"2021","journal-title":"Cell Death Dis."},{"issue":"10","key":"10.1016\/j.intimp.2022.109046_b0140","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1182\/blood.2021013768","article-title":"Effectiveness of the BNT162b2mRNA Covid-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting","volume":"139","author":"Mittelman","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2022.109046_b0145","article-title":"COVID-19 in vaccinated adult patients with hematological malignancies. Preliminary results from EPICOVIDEHA","author":"Pagano","year":"2021","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.intimp.2022.109046_b0150","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.3390\/cancers13143573","article-title":"COVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience","volume":"13","author":"So","year":"2021","journal-title":"Cancers."},{"issue":"8","key":"10.1016\/j.intimp.2022.109046_b0155","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jgo.2021.06.002","article-title":"Serological response to COVID-19 vaccination in patients with cancer older than 80 years","volume":"12","author":"Iacono","year":"2021","journal-title":"J. Geriatric Oncology"},{"issue":"1","key":"10.1016\/j.intimp.2022.109046_b0160","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01190-3","article-title":"Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients","volume":"14","author":"Canti","year":"2021","journal-title":"J. Hematol. & Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2022.109046_b0165","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1016\/S2352-3026(21)00169-1","article-title":"Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study","volume":"8","author":"Maneikis","year":"2021","journal-title":"The Lancet Haematology."},{"issue":"1","key":"10.1016\/j.intimp.2022.109046_b0170","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1200\/JCO.21.01891","article-title":"Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with cancer: the CANVAX cohort study","volume":"40","author":"Naranbhai","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2022.109046_b0175","doi-asserted-by":"crossref","DOI":"10.3332\/ecancer.2021.1284","article-title":"COVID-19 vaccination immune response in patients with solid organ and haematologic malignancies: call for active monitoring","volume":"15","author":"Chehade","year":"2021","journal-title":"ecancermedicalscience."},{"key":"10.1016\/j.intimp.2022.109046_b0180","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejca.2021.06.002","article-title":"The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience","volume":"154","author":"Revon-Riviere","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"11","key":"10.1016\/j.intimp.2022.109046_b0185","doi-asserted-by":"crossref","first-page":"E443","DOI":"10.1002\/ajh.26348","article-title":"Antibody response to COVID-19 mRNA vaccine (Comirnaty) in myeloma patients treated with high-dose melphalan and\/or immunotherapy","volume":"96","author":"Lockmer","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"10","key":"10.1016\/j.intimp.2022.109046_b0190","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.ccell.2021.09.001","article-title":"Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies","volume":"39","author":"Greenberger","year":"2021","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.intimp.2022.109046_b0195","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.ccell.2021.06.015","article-title":"Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient","volume":"39","author":"Hill","year":"2021","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.intimp.2022.109046_b0200","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.17911","article-title":"Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant","volume":"196","author":"Le Bourgeois","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.intimp.2022.109046_b0205","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.3390\/vaccines9101055","article-title":"Antibody Responses after a Third Dose of COVID-19 Vaccine in Kidney Transplant Recipients and Patients Treated for Chronic Lymphocytic Leukemia","volume":"9","author":"Marlet","year":"2021","journal-title":"Vaccines."},{"issue":"Supplement 1","key":"10.1016\/j.intimp.2022.109046_b0210","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-151367","article-title":"Production of Anti-Spike Antibodies in Response to COVID Vaccine in Lymphoma Patients","volume":"138","author":"Della Pia","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.intimp.2022.109046_b0215","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1182\/blood-2021-152954","article-title":"Neutralizing Antibody Responses Against Sars-Cov-2 in Patients with Plasma Cell Disorders Who Are on Active Treatment after Two Doses of mRNA Vaccination","volume":"138","author":"Abdallah","year":"2021","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.intimp.2022.109046_b0220","doi-asserted-by":"crossref","first-page":"6460","DOI":"10.1111\/jcmm.16565","article-title":"Immunogenicity and safety of BNT162b2 COVID-19 vaccine in a chronic lymphocytic leukaemia patient","volume":"25","author":"Agrati","year":"2021","journal-title":"J. Cell Mol. Med."},{"issue":"7","key":"10.1016\/j.intimp.2022.109046_b0225","doi-asserted-by":"crossref","first-page":"737","DOI":"10.3390\/vaccines9070737","article-title":"Anti-SARS-CoV-2 Immune Responses in Patients Receiving an Allogeneic Stem Cell or Organ Transplant","volume":"9","author":"Atanackovic","year":"2021","journal-title":"Vaccines"},{"issue":"11","key":"10.1016\/j.intimp.2022.109046_b0230","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.ccell.2021.09.015","article-title":"Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma","volume":"39","author":"Aleman","year":"2021","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.intimp.2022.109046_b0235","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1080\/10428194.2021.1998485","article-title":"Cellular response to COVID-19 vaccines in hematologic malignancies patients: a new hope for non-responders?","volume":"63","author":"Saad Albichr","year":"2022","journal-title":"Leukemia & Lymphoma"},{"issue":"2","key":"10.1016\/j.intimp.2022.109046_b0240","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/bjh.17821","article-title":"The 12-week kinetics of anti-SARS-CoV-2 antibodies in different haematological cancers after vaccination with BNT162b2","volume":"196","author":"Marchesi","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.intimp.2022.109046_b0245","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.704110","article-title":"COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial","volume":"12","author":"Agrati","year":"2021","journal-title":"Front. Immunol."},{"issue":"16","key":"10.1016\/j.intimp.2022.109046_b0250","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1002\/cncr.33598","article-title":"Cocooning against COVID-19: The argument for vaccinating caregivers of patients with cancer","volume":"127","author":"Woodfield","year":"2021","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.intimp.2022.109046_b0255","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.ccell.2021.06.009","article-title":"Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer","volume":"39","author":"Addeo","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2022.109046_b0260","series-title":"Suboptimal response to coronavirus disease 2019 messenger RNA vaccines in patients with hematologic malignancies: a need for vigilance in the postmasking era. Open forum infectious diseases","year":"2021"},{"key":"10.1016\/j.intimp.2022.109046_b0265","doi-asserted-by":"crossref","unstructured":"A. Aleman, B. Upadhyaya, K. Tuballes, K. Kappes, C.R. Gleason, K. Beach, et al., Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma, Cancer Cell. 2021;39(11):1442\u20131444.","DOI":"10.1016\/j.ccell.2021.09.015"},{"key":"10.1016\/j.intimp.2022.109046_b0270","first-page":"1","article-title":"Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy","author":"Ariamanesh","year":"2021","journal-title":"Cancer Investigation"},{"issue":"2","key":"10.1016\/j.intimp.2022.109046_b0275","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/bjh.17608","article-title":"Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma","volume":"195","author":"Avivi","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109046_b0280","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/bjh.17743","article-title":"Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients","volume":"195","author":"Benda","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.intimp.2022.109046_b0285","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2021.279196","article-title":"Safety and efficacy of BNT162b mRNA Covid19 Vaccine in patients with chronic lymphocytic leukemia","author":"Benjamini","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.intimp.2022.109046_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103705","article-title":"Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial","volume":"74","author":"Bergman","year":"2021","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.intimp.2022.109046_b0295","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3026(21)00110-1","article-title":"Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma","volume":"8","author":"Bird","year":"2021","journal-title":"The Lancet Haematology"},{"issue":"1","key":"10.1016\/j.intimp.2022.109046_b0300","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01183-2","article-title":"Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls","volume":"14","author":"Bitoun","year":"2021","journal-title":"J. Hematol. & Oncology"},{"issue":"4","key":"10.1016\/j.intimp.2022.109046_b0305","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s00277-021-04613-w","article-title":"Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis","volume":"101","author":"Caocci","year":"2022","journal-title":"Ann. Hematol."},{"issue":"11","key":"10.1016\/j.intimp.2022.109046_b0310","article-title":"Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience. Blood","volume":"11","author":"Cattaneo","year":"2021","journal-title":"Cancer J."},{"issue":"3","key":"10.1016\/j.intimp.2022.109046_b0315","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.17864","article-title":"Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors","volume":"196","author":"Chan","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109046_b0320","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/jha2.242","article-title":"Safety and immunogenicity of a first dose of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem-cells recipients","volume":"2","author":"Chevallier","year":"2021","journal-title":"eJHaem."},{"key":"10.1016\/j.intimp.2022.109046_b0325","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.737300","article-title":"Immunological Response Against SARS-COV-2 After BNT162b2 Vaccine Administration Is Impaired in Allogeneic but Not in Autologous Stem Cell Transplant Recipients","volume":"11","author":"Chiarucci","year":"2021","journal-title":"Front Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2022.109046_b0330","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/bjh.17644","article-title":"Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms","volume":"194","author":"Chowdhury","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.intimp.2022.109046_b0335","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1158\/2643-3230.BCD-21-0139","article-title":"Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies","volume":"2","author":"Chung","year":"2021","journal-title":"Blood Cancer Discov."},{"issue":"16","key":"10.1016\/j.intimp.2022.109046_b0340","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/bloodadvances.2021005328","article-title":"Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies","volume":"5","author":"Crombie","year":"2021","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.intimp.2022.109046_b0345","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/hon.2916","article-title":"COVID-19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients","volume":"39","author":"Del Poeta","year":"2021","journal-title":"Hematol. Oncol."},{"issue":"14","key":"10.1016\/j.intimp.2022.109046_b0350","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1182\/blood.2021012769","article-title":"Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy","volume":"138","author":"Dhakal","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.intimp.2022.109046_b0355","first-page":"880.e1","article-title":"Serologic Responses following a Single Dose of SARS-Cov-2 Vaccination in Allogeneic Stem Cell Transplantation Recipients. Transplantation and Cellular","volume":"27","author":"Easdale","year":"2021","journal-title":"Therapy."},{"issue":"8","key":"10.1016\/j.intimp.2022.109046_b0360","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.ccell.2021.07.016","article-title":"Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer","volume":"39","author":"Ehmsen","year":"2021","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.intimp.2022.109046_b0365","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s43018-021-00274-w","article-title":"Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study","volume":"2","author":"Fendler","year":"2021","journal-title":"Nature Cancer."},{"issue":"24","key":"10.1016\/j.intimp.2022.109046_b0370","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.1158\/0008-5472.CAN-21-3554","article-title":"Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer","volume":"81","author":"Figueiredo","year":"2021","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.intimp.2022.109046_b0375","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3390\/biomedicines9101480","article-title":"The Slower Antibody Response in Myelofibrosis Patients after Two Doses of mRNA SARS-CoV-2 Vaccine Calls for a Third Dose","volume":"9","author":"Fiorino","year":"2021","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.intimp.2022.109046_b0380","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/bjh.17836","article-title":"Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies","volume":"195","author":"Fox","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109046_b0385","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10238-021-00746-4","article-title":"Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine","volume":"22","author":"Gavriatopoulou","year":"2022","journal-title":"Clin. Exp. Med."},{"issue":"21","key":"10.1016\/j.intimp.2022.109046_b0390","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1182\/bloodadvances.2021005444","article-title":"Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study","volume":"5","author":"Gavriatopoulou","year":"2021","journal-title":"Blood Adv."},{"issue":"15","key":"10.1016\/j.intimp.2022.109046_b0395","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.3390\/cancers13153800","article-title":"Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment","volume":"13","author":"Ghandili","year":"202113153800","journal-title":"Cancers."},{"issue":"9","key":"10.1016\/j.intimp.2022.109046_b0400","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.2021012443","article-title":"Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell\u2013directed therapies","volume":"138","author":"Ghione","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.intimp.2022.109046_b0405","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ccell.2021.07.012","article-title":"Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies","volume":"39","author":"Greenberger","year":"2021","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.intimp.2022.109046_b0410","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26305","article-title":"Impaired response to first SARS-CoV -2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib","volume":"96","author":"Guglielmelli","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.intimp.2022.109046_b0415","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2021.279216","article-title":"Humoral serologic response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies","author":"Gurion","year":"2021","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.intimp.2022.109046_b0420","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1038\/s41375-021-01300-7","article-title":"Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms","volume":"35","author":"Harrington","year":"2021","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.intimp.2022.109046_b0425","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/bjh.17568","article-title":"Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia","volume":"194","author":"Harrington","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"23","key":"10.1016\/j.intimp.2022.109046_b0430","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.intimp.2022.109046_b0435","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/ajh.26284","article-title":"BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies","volume":"96","author":"Herzog Tzarfati","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"11","key":"10.1016\/j.intimp.2022.109046_b0440","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26322","article-title":"Serologic response to mRNA COVID -19 vaccination in lymphoma patients","volume":"96","author":"Jurgens","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"12","key":"10.1016\/j.intimp.2022.109046_b0445","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1038\/s41375-021-01457-1","article-title":"Serum antibody response in patients with philadelphia-chromosome positive or negative myeloproliferative neoplasms following vaccination with SARS-CoV-2 spike protein messenger RNA (mRNA) vaccines","volume":"35","author":"Kozak","year":"2021","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.intimp.2022.109046_b0450","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.26344","article-title":"Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant","volume":"4","author":"Le Bourgeois","year":"2021","journal-title":"JAMA Network Open"},{"issue":"8","key":"10.1016\/j.intimp.2022.109046_b0455","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S2352-3026(21)00199-X","article-title":"Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma","volume":"8","author":"Lim","year":"2021","journal-title":"The Lancet Haematology"},{"issue":"10","key":"10.1016\/j.intimp.2022.109046_b0460","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3390\/vaccines9101075","article-title":"Humoral and Cellular Vaccination Responses against SARS-CoV-2 in Hematopoietic Stem Cell Transplant Recipients","volume":"9","author":"Lindemann","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.intimp.2022.109046_b0465","article-title":"Cellular and humoral Immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia","author":"Lyski","year":"2021","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.intimp.2022.109046_b0470","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1001\/jamaoncol.2021.5437","article-title":"Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations","volume":"8","author":"Mair","year":"2022","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2022.109046_b0475","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.ccell.2021.08.001","article-title":"Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer","volume":"39","author":"Mairhofer","year":"2021","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.intimp.2022.109046_b0480","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00534-z","article-title":"Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies","volume":"11","author":"Malard","year":"2021","journal-title":"Blood Cancer J."},{"issue":"3","key":"10.1016\/j.intimp.2022.109046_b0485","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/bjh.17877","article-title":"T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies","volume":"196","author":"Marasco","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109046_b0490","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41375-021-01418-8","article-title":"Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin\u2019s lymphomas","volume":"36","author":"Marchesi","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.intimp.2022.109046_b0495","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.ccell.2021.10.003","article-title":"Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer","volume":"39","author":"McKenzie","year":"2021","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.intimp.2022.109046_b0500","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","article-title":"Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study","volume":"22","author":"Monin","year":"2021","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.intimp.2022.109046_b0505","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1001\/jamaoncol.2021.4381","article-title":"Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease","volume":"7","author":"Ollila","year":"2021","journal-title":"JAMA Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2022.109046_b0510","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00528-x","article-title":"Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia","volume":"11","author":"Parry","year":"2021","journal-title":"Blood Cancer J."},{"issue":"5","key":"10.1016\/j.intimp.2022.109046_b0515","doi-asserted-by":"crossref","first-page":"100274","DOI":"10.1016\/j.esmoop.2021.100274","article-title":"Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment","volume":"6","author":"Peeters","year":"2021","journal-title":"ESMO Open."},{"issue":"16","key":"10.1016\/j.intimp.2022.109046_b0520","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/bloodadvances.2021005094","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma","volume":"5","author":"Perry","year":"2021","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.intimp.2022.109046_b0525","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01090-6","article-title":"Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution","volume":"14","author":"Pimpinelli","year":"2021","journal-title":"J. Hematol. & Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109046_b0530","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01130-1","article-title":"Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia","volume":"14","author":"Pimpinelli","year":"2021","journal-title":"J. Hematol. & Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109046_b0535","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ajh.26385","article-title":"SARS-CoV -2-reactive antibody detection after SARS-CoV -2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group","volume":"97","author":"Pi\u00f1ana","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.intimp.2022.109046_b0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101158","article-title":"BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study","volume":"41","author":"Rahav","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"9","key":"10.1016\/j.intimp.2022.109046_b0545","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jtct.2021.06.024","article-title":"Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study","volume":"27","author":"Ram","year":"2021","journal-title":"Transplant Cell Ther."},{"key":"10.1016\/j.intimp.2022.109046_b0550","article-title":"COVID symptoms, testing, shielding impact on patient-reported outcomes and early vaccine responses in individuals with multiple myeloma","author":"Ramasamy","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"13","key":"10.1016\/j.intimp.2022.109046_b0555","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1080\/10428194.2021.1957877","article-title":"Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies","volume":"62","author":"Re","year":"2021","journal-title":"Leukemia & Lymphoma"},{"issue":"10297","key":"10.1016\/j.intimp.2022.109046_b0560","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(21)01594-4","article-title":"Antibody response after second BNT162b2 dose in allogeneic HSCT recipients","volume":"398","author":"Redjoul","year":"2021","journal-title":"The Lancet"},{"issue":"9","key":"10.1016\/j.intimp.2022.109046_b0565","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1038\/s41375-021-01270-w","article-title":"COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia","volume":"35","author":"Roeker","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.intimp.2022.109046_b0570","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41409-021-01487-4","article-title":"Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation","volume":"57","author":"Salvini","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.intimp.2022.109046_b0575","doi-asserted-by":"crossref","first-page":"E475","DOI":"10.1002\/ajh.26373","article-title":"Attenuated humoral immune response following anti-SARS-CoV-2 vaccine in heavily pretreated patients with multiple myeloma and AL amyloidosis","volume":"96","author":"Schiller Salton","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109046_b0580","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/bjh.17918","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients","volume":"196","author":"Shem\u2010Tov","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.intimp.2022.109046_b0585","article-title":"COVID-19 Vaccine Failure in Chronic Lymphocytic Leukaemia and Monoclonal B-Lymphocytosis; Humoral and Cellular Immunity","author":"Shen","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.intimp.2022.109046_b0590","article-title":"Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Immunogenicity and Reactogenicity","author":"Sherman","year":"2021","journal-title":"Clin. Infect. Dis."},{"issue":"17","key":"10.1016\/j.intimp.2022.109046_b0595","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.3390\/cancers13174312","article-title":"Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients","volume":"13","author":"Singer","year":"2021","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.intimp.2022.109046_b0600","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1038\/s41375-021-01354-7","article-title":"Response to mRNA vaccination for COVID-19 among patients with multiple myeloma","volume":"35","author":"Stampfer","year":"2021","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.intimp.2022.109046_b0605","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1038\/s41375-021-01380-5","article-title":"Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia","volume":"35","author":"Tadmor","year":"2021","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.intimp.2022.109046_b0610","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/2643-3230.BCD-21-0142","article-title":"Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy","volume":"2","author":"Tamari","year":"2021","journal-title":"Blood Cancer Discovery"},{"issue":"17","key":"10.1016\/j.intimp.2022.109046_b0615","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.3390\/cancers13174480","article-title":"Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study","volume":"13","author":"Terpos","year":"2021","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.intimp.2022.109046_b0620","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00530-3","article-title":"The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment","volume":"11","author":"Terpos","year":"2021","journal-title":"Blood Cancer J."},{"issue":"26","key":"10.1016\/j.intimp.2022.109046_b0625","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1182\/blood.2021011904","article-title":"Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose","volume":"137","author":"Terpos","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.intimp.2022.109046_b0630","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ccell.2021.06.002","article-title":"Seroconversion rates following COVID-19 vaccination among patients with cancer","volume":"39","author":"Thakkar","year":"2021","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.intimp.2022.109046_b0635","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ccell.2021.06.014","article-title":"Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma","volume":"39","author":"Van Oekelen","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2022.109046_b0640","article-title":"Humoral serological response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation","author":"Yeshurun","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"issue":"1","key":"10.1016\/j.intimp.2022.109046_b0645","doi-asserted-by":"crossref","DOI":"10.1186\/s13578-021-00713-2","article-title":"Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients","volume":"11","author":"Zeng","year":"2021","journal-title":"Cell & Biosci."},{"key":"10.1016\/j.intimp.2022.109046_b0650","unstructured":"G. Haidar, M. Agha, A. Lukanski, K. Linstrum, R. Troyan, A. Bilderback, et al., Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients: An Observational, Prospective Cohort Study Interim Analysis, medRxiv, 2021:2021.06.28.21259576."},{"key":"10.1016\/j.intimp.2022.109046_b0655","doi-asserted-by":"crossref","unstructured":"P. Kearns, S. Siebert, C. Gaskell, A. Kirkham, S. Pirrie, S. Bowden, et al. Examining the immunological effects of COVID-19 vaccination in patients with conditions potentially leading to diminished immune response capacity\u2013the OCTAVE trial, 2021.","DOI":"10.2139\/ssrn.3910058"},{"key":"10.1016\/j.intimp.2022.109046_b0660","doi-asserted-by":"crossref","unstructured":"L.C. Shapiro, A. Thakkar, R. Gali, J.D. Gonzalez-Lugo, A.-H. Bazarbachi, S. Rahman, et al., High Seroconversion Rates Amongst Black and Hispanics With Hematologic Malignancies after SARS-CoV-2 Vaccination, medRxiv, 2021:2021.09.13.21263365.","DOI":"10.1101\/2021.09.13.21263365"},{"key":"10.1016\/j.intimp.2022.109046_b0665","article-title":"Immunogenicity of COVID-19 vaccines in patients with hematological malignancy: a systematic review and meta-analysis","author":"Teh","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.intimp.2022.109046_b0670","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.759108","article-title":"Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review","volume":"11","author":"Guven","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.intimp.2022.109046_b0675","article-title":"COVID-19 in vaccinated adult patients with hematological malignancies. Preliminary results from EPICOVIDEHA","author":"Pagano","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.intimp.2022.109046_b0680","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/ejh.13729","article-title":"mRNA COVID-19 vaccines in patients with chronic lymphocytic leukemia: A systematic review and meta-analysis","volume":"108","author":"Molica","year":"2022","journal-title":"Eur. J. Haematol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109046_b0685","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/ejh.13722","article-title":"Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia","volume":"108","author":"Morawska","year":"2022","journal-title":"Eur. J. Haematol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109046_b0690","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.25039","article-title":"Good and bad memories following rituximab therapy","volume":"62","author":"St.Clair","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2022.109046_b0695","doi-asserted-by":"crossref","unstructured":"N.A.M. Hamed, New COVID Vaccines and Hematological Cancers, Canc Therapy & Oncol. Int. J. 2021;19(1).","DOI":"10.19080\/CTOIJ.2021.19.556001"},{"issue":"1","key":"10.1016\/j.intimp.2022.109046_b0700","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.15562\/bmj.v10i1.2273","article-title":"COVID-19 vaccination in patients with cancer: Position paper from the Indonesian Society of Hematology and Medical Oncology (ISHMO) of Semarang","volume":"10","author":"Pangarsa","year":"2021","journal-title":"Bali Med. J."},{"key":"10.1016\/j.intimp.2022.109046_b0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108021","article-title":"Administration of COVID-19 vaccines in immunocompromised patients","volume":"99","author":"Negahdaripour","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2022.109046_b0710","doi-asserted-by":"crossref","unstructured":"S.H. Lim, M. Ahearne, Impaired immune responses in blood cancers improved by third COVID-19 vaccine dose, NATURE PORTFOLIO HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY; 2022.","DOI":"10.1038\/s43018-022-00369-y"},{"issue":"3","key":"10.1016\/j.intimp.2022.109046_b0715","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/bjh.18073","article-title":"Third dose of COVID-19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres","volume":"197","author":"\u0160u\u0161ol","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.intimp.2022.109046_b0720","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejca.2022.01.019","article-title":"Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events\u2013a retrospective cohort study","volume":"165","author":"Mair","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.intimp.2022.109046_b0725","article-title":"Antibody response after vaccination against SARS-CoV-2 in adults with haematological malignancies: a systematic review and meta-analysis","author":"Gagelmann","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.intimp.2022.109046_b0730","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-021-02055-9","article-title":"Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals","volume":"19","author":"Fraley","year":"2021","journal-title":"BMC Med."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922005306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922005306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:45:16Z","timestamp":1761587116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922005306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":146,"alternative-id":["S1567576922005306"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109046","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109046"}}